Literature DB >> 540882

[Cardiovascular pharmacology of cinepazide, a new cerebral vasodilator (author's transl)].

A Akashi, M Hirohashi, I Suzuki, S Shibamura, A Kasahara.   

Abstract

Cardiovascular effects of cinepazide were compared with those of cinnarizine and papaverine. Cinepazide (3-30 mg/kg, i.v.) produced a dose-related and transient increase in vertebral, carotid, renal and femoral arterial flow as well as cardiac output and a decrease in total peripheral resistance in anesthetized dogs. The magnitude and duration of mesenteric vasodilatation induced by cinepazide was much greater as compared to other vascular effects, and these effects were associated with a prolonged hypotension. The drug exerted positive inotropic and chronotropic actions, the latter being followed by bradycardia with the highest dose. Cinnarizine (0.3-3 mg/kg, i.v.) produced a greater increase in vertebral blood flow with bradycardia and papaverine (0.1-1 mg/kg, i.v.) produced a remarkable carotid vasodilatation with cardiac stimulation. Both reference drugs decreased renal blood flow. Cinepazide (30 mg/kg, i.v.) potentiated the vertebral vasodilator response of dogs to intravertebral adenosine and cyclic AMP, while cinnarizine (3 mg/kg i.v.) reduced their vasodilator effects. Intravertebral cinepazide(1-10 mg), like cinnarizine (0.1-1 mg) and papaverine (0.1-1 mg), increased vertebral blood flow in a dose-related manner and the effect was partially inhibited by intravenous pretreatment with aminophylline but not by pretreatment with autonomic antagonists. These antagonists did not modify the cinnarizine effect. Cinepazide resembled cinnarizine and papaverine in that the drug antagonized rabbit aortic contraction induced by KCl, norepinephrine or CaCl2.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 540882     DOI: 10.1254/fpj.75.507

Source DB:  PubMed          Journal:  Nihon Yakurigaku Zasshi        ISSN: 0015-5691


  2 in total

1.  Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial.

Authors:  Yi Zhu; Guangyun Zhang; Jun Zhao; Deshuai Li; Xiaodong Yan; Juanfang Liu; Xuedong Liu; Haibo Zhao; Jielai Xia; Xiao Zhang; Zhengyi Li; Baorong Zhang; Zongcheng Guo; Lianyuan Feng; Zhaodong Zhang; Fang Qu; Gang Zhao
Journal:  Clin Drug Investig       Date:  2013-10       Impact factor: 2.859

2.  Edaravone combined with cinepazide maleate on neurocyte autophagy and neurological function in rats with subarachnoid hemorrhage.

Authors:  Zhenli Cai; Haidong Zhang; Hongshan Song; Ying Piao; Xiaoye Zhang
Journal:  Exp Ther Med       Date:  2019-11-25       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.